Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Revenue projections:

With BAX's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio	1.946000
forwardPE	12.394709
debtToEquity	156.449000
earningsGrowth	0.368000
revenueGrowth	0.053000
grossMargins	0.340980
operatingMargins	0.144260
trailingEps	-1.880000
forwardEps	2.039580

Baxter International Inc.'s current ratio, being 1.946, means the company is well-positioned to meet its short-term debt obligations. This reflects Baxter International Inc.'s strong liquidity, as its cash reserves and current assets provide more than enough coverage for its immediate liabilities.
BAX's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
BAX's high debt-to-equity ratio shows the company is significantly leveraged, relying heavily on debt financing. This raises the potential for increased financial risk, especially if the company's earnings or cash flow are negatively impacted.

Price projections:

The price of Baxter International Inc. has consistently remained close to the lower end of price projections. This trend may reflect uncertainty in the market regarding the company's ability to deliver on growth expectations.

Recommendation changes over time:

The recent buy bias from analysts suggests BAX is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, BAX appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.